Article info

PDF
Original Article
Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with inflammatory bowel disease

Authors

  • Sebastian Zeissig Department of Medicine I, Universitätsklinikum Carl Gustav Carus Dresden, Technische Universität (TU) Dresden, Dresden, GermanyCenter for Regenerative Therapies Dresden, Technische Universität (TU) Dresden, Dresden, GermanyDepartment of Internal Medicine I, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany PubMed articlesGoogle scholar articles
  • Elisa Rosati Institute of Clinical Molecular Biology, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany PubMed articlesGoogle scholar articles
  • C Marie Dowds Department of Internal Medicine I, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, GermanyInstitute of Clinical Molecular Biology, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany PubMed articlesGoogle scholar articles
  • Konrad Aden Department of Internal Medicine I, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, GermanyInstitute of Clinical Molecular Biology, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany PubMed articlesGoogle scholar articles
  • Johannes Bethge Department of Internal Medicine I, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany PubMed articlesGoogle scholar articles
  • Berenice Schulte Department of Internal Medicine I, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany PubMed articlesGoogle scholar articles
  • Wei Hung Pan Institute of Clinical Molecular Biology, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany PubMed articlesGoogle scholar articles
  • Neha Mishra Institute of Clinical Molecular Biology, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany PubMed articlesGoogle scholar articles
  • Maaz Zuhayra Department of Nuclear Medicine, Molecular Diagnostic Imaging and Therapy, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany PubMed articlesGoogle scholar articles
  • Marlies Marx Department of Nuclear Medicine, Molecular Diagnostic Imaging and Therapy, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany PubMed articlesGoogle scholar articles
  • Maren Paulsen Institute of Clinical Molecular Biology, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany PubMed articlesGoogle scholar articles
  • Anne Strigli Department of Medicine I, Universitätsklinikum Carl Gustav Carus Dresden, Technische Universität (TU) Dresden, Dresden, GermanyCenter for Regenerative Therapies Dresden, Technische Universität (TU) Dresden, Dresden, Germany PubMed articlesGoogle scholar articles
  • Claudio Conrad Department of Internal Medicine I, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany PubMed articlesGoogle scholar articles
  • Dörthe Schuldt Department of Internal Medicine I, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany PubMed articlesGoogle scholar articles
  • Anupam Sinha Institute of Clinical Molecular Biology, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany PubMed articlesGoogle scholar articles
  • Henriette Ebsen Institute of Immunology, Christian-Albrechts-Universität zu Kiel, Kiel, Germany PubMed articlesGoogle scholar articles
  • Sabin-Christin Kornell Department of Internal Medicine I, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, GermanyInstitute of Clinical Molecular Biology, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany PubMed articlesGoogle scholar articles
  • Susanna Nikolaus Department of Internal Medicine I, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany PubMed articlesGoogle scholar articles
  • Alexander Arlt Department of Internal Medicine I, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany PubMed articlesGoogle scholar articles
  • Dieter Kabelitz Institute of Immunology, Christian-Albrechts-Universität zu Kiel, Kiel, Germany PubMed articlesGoogle scholar articles
  • Mark Ellrichmann Department of Internal Medicine I, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany PubMed articlesGoogle scholar articles
  • Ulf Lützen Department of Nuclear Medicine, Molecular Diagnostic Imaging and Therapy, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany PubMed articlesGoogle scholar articles
  • Philip C Rosenstiel Institute of Clinical Molecular Biology, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany PubMed articlesGoogle scholar articles
  • Andre Franke Institute of Clinical Molecular Biology, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany PubMed articlesGoogle scholar articles
  • Stefan Schreiber Department of Internal Medicine I, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, GermanyInstitute of Clinical Molecular Biology, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Sebastian Zeissig, Department of Medicine I, Universitätsklinikum Carl Gustav Carus Dresden, Technische Universität (TU) Dresden, Dresden 01307, Germany; sebastian.zeissig{at}tu-dresden.de and Dr Stefan Schreiber, Department of Internal Medicine I, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany; s.schreiber{at}mucosa.de
View Full Text

Citation

Zeissig S, Rosati E, Dowds CM, et al
Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with inflammatory bowel disease

Publication history

  • Received January 13, 2018
  • Revised April 3, 2018
  • Accepted April 17, 2018
  • First published May 5, 2018.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.